Development of CAR-Treg Therapies to Induce Immune Tolerance – Path to the Clinic
Time: 1:00 pm
day: Day Two Track B, PM
Details:
• Description of Quell Therapeutic’s platform to generate CAR-Treg products with enhanced safety and efficacy
• Analysis of the current outcomes from the clinical experience with CAR-Tregs in liver transplantation
NEW DATA
